Heidenreich A, Moul J W, McLeod D G, Mostofi F K, Engelmann U H
Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
J Urol. 1997 Jan;157(1):160-3.
Pure testicular teratoma is rare in adulthood with an incidence of 5%. Pure teratoma is considered less aggressive and less likely to metastasize than other nonseminomatous germ cell tumors. Therefore, patients with mature teratoma have been considered candidates for surveillance protocols. We report our experience with 44 cases of primary pure testicular teratoma.
We retrospectively identified 44 patients (5.7%) with primary pure teratoma of the testis of the 772 treated for testicular germ cell tumors at our institutions. Archival tumor blocks were available for pathological reevaluation and serial sections were obtained in all cases. A total of 35 patients (79.5%) who presented with clinical low stage disease, including stage I in 26 (59.1%) and stage IIA/B in 9 (20.4%), underwent radical orchiectomy followed by retroperitoneal lymphadenectomy. Nine patients (20.5%) who presented with clinically advanced disease (stages IIC to IV) were treated with primary chemotherapy and secondary retroperitoneal lymphadenectomy of residual masses.
The frequency of lymph node metastases was 19.2% in clinical stage I disease and 66% in stage IIA/B. Histopathological diagnosis of mature teratoma was confirmed in all cases. However, of 20 patients 16 (80%) had scars or calcifications in the adjacent parenchyma, indicating a burned out tumor, and 4 (20%) had microfocal embryonal carcinoma. None of the patients with clinical stage I disease had relapse during followup and the relapse rate in those with stage IIA/B disease was 33%. Median followup was 97 months (range 24 to 250). Overall 43% of patients with pure teratoma presented with metastatic disease.
Our data demonstrate the malignant potential of pure testicular mature teratoma. Based on our results metastases in testicular mature teratoma seem to result from metastasizing nongerm cell components undergoing early regression, as demonstrated by the high frequency of burned out tumors. We recommend that serial sections be taken of the orchiectomy specimen in all cases of pure mature teratoma to determine adequate management: retroperitoneal lymphadenectomy in cases of associated scars, calcifications or microfocal malignant germ cell components and surveillance in cases of pure mature teratoma.
纯睾丸畸胎瘤在成年期罕见,发病率为5%。与其他非精原细胞瘤性生殖细胞肿瘤相比,纯畸胎瘤的侵袭性较小,转移的可能性也较小。因此,成熟畸胎瘤患者一直被视为监测方案的候选者。我们报告了44例原发性纯睾丸畸胎瘤的治疗经验。
我们回顾性分析了在我们机构接受睾丸生殖细胞肿瘤治疗的772例患者中44例(5.7%)原发性纯睾丸畸胎瘤患者。可获得存档肿瘤块用于病理重新评估,并对所有病例进行连续切片。共有35例(79.5%)临床低分期疾病患者,其中26例(59.1%)为I期,9例(20.4%)为IIA/B期,接受了根治性睾丸切除术,随后进行腹膜后淋巴结清扫术。9例(20.5%)临床晚期疾病(IIC至IV期)患者接受了一线化疗和残余肿块的二线腹膜后淋巴结清扫术。
临床I期疾病的淋巴结转移率为19.2%,IIA/B期为66%。所有病例均确诊为成熟畸胎瘤的组织病理学诊断。然而,在20例患者中,16例(80%)在相邻实质中有瘢痕或钙化,表明肿瘤已消退,4例(20%)有微灶性胚胎癌。临床I期疾病患者在随访期间均未复发,IIA/B期疾病患者的复发率为33%。中位随访时间为97个月(范围24至250个月)。总体而言,43%的纯畸胎瘤患者出现转移性疾病。
我们的数据证明了纯睾丸成熟畸胎瘤的恶性潜能。根据我们的结果,睾丸成熟畸胎瘤的转移似乎是由于转移的非生殖细胞成分早期消退所致,这在消退的肿瘤中很常见。我们建议对所有纯成熟畸胎瘤病例的睾丸切除标本进行连续切片,以确定适当的治疗方案:对于伴有瘢痕、钙化或微灶性恶性生殖细胞成分的病例进行腹膜后淋巴结清扫术,对于纯成熟畸胎瘤病例进行监测。